R.N. Safin1, R.Sh. Khasanov2
1Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal, Kazan
2Kazan State Medical Academy ― Branch Campus of the FSBEI FPE RMACPE MOH Russia, Kazan
Safin Rustem N. ― oncologist, head of chemotherapy department of Republican Clinical Oncology Dispensary of Ministry of Healthcare of Tatarstan Republic named after prof. M.Z. Sigal
29 Sibirskiy trakt, Kazan, 420029, Russian Federation, tel. +7-917-272-79-93, e-mail: firstname.lastname@example.org, ORCID ID: 0000-0003-0585-7727
Abstract. Breast cancer is the most common form of malignant neoplasms in the female population in the world. The choice of treatment tactics is based on the stage of the disease, the biological characteristics of the tumor and includes various combinations of drug therapy, surgical treatment and radiation therapy. Systemic drug therapy in its various variants is used both in the case of primary metastatic breast cancer and in localized stages (I-III). Breast cancer with Her2 overexpression accounts for 20-30% among all subtypes. Neoadjuvant drug therapy of breast cancer sets itself such tasks as: assessing the sensitivity of the tumor to a certain therapy regimen, achieving maximum drug pathomorphosis of the tumor, converting primary inoperable forms of the tumor into operable ones, increasing the proportion of organ-preserving surgical interventions. Achieving a complete pathomorphological response to neoadjuvant therapy can improve the survival of patients with Her2-positive breast cancer.
Key words: Her2-positive breast cancer, neoadjuvant chemotherapy, pathomorphological response, trastuzumab, pertuzumab.